This article has been updated with a comment from BGI's subsidiary Complete Genomics.
NEW YORK – BGI and its subsidiaries MGI and Complete Genomics have sued Illumina for violation of federal antitrust and California unfair competition laws, claiming that Illumina used "fraudulent behavior" to obtain or enforce three sequencing patents that it has asserted against BGI, preventing that firm from entering the US market with its CoolMPS sequencing technology.